Thiocolchicoside

Jump to navigation Jump to search
Thiocolchicoside
Clinical data
ATC code
Identifiers
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H33NO10S
Molar mass563.618 g/mol
Thiocolchicoside
Thiocolchicoside.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, Topical, IM
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability25%[1]
Elimination half-life5-6 hours[1][2]
Identifiers
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H33NO10S
Molar mass563.618 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)


WikiDoc Resources for Thiocolchicoside

Articles

Most recent articles on Thiocolchicoside

Most cited articles on Thiocolchicoside

Review articles on Thiocolchicoside

Articles on Thiocolchicoside in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Thiocolchicoside

Images of Thiocolchicoside

Photos of Thiocolchicoside

Podcasts & MP3s on Thiocolchicoside

Videos on Thiocolchicoside

Evidence Based Medicine

Cochrane Collaboration on Thiocolchicoside

Bandolier on Thiocolchicoside

TRIP on Thiocolchicoside

Clinical Trials

Ongoing Trials on Thiocolchicoside at Clinical Trials.gov

Trial results on Thiocolchicoside

Clinical Trials on Thiocolchicoside at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Thiocolchicoside

NICE Guidance on Thiocolchicoside

NHS PRODIGY Guidance

FDA on Thiocolchicoside

CDC on Thiocolchicoside

Books

Books on Thiocolchicoside

News

Thiocolchicoside in the news

Be alerted to news on Thiocolchicoside

News trends on Thiocolchicoside

Commentary

Blogs on Thiocolchicoside

Definitions

Definitions of Thiocolchicoside

Patient Resources / Community

Patient resources on Thiocolchicoside

Discussion groups on Thiocolchicoside

Patient Handouts on Thiocolchicoside

Directions to Hospitals Treating Thiocolchicoside

Risk calculators and risk factors for Thiocolchicoside

Healthcare Provider Resources

Symptoms of Thiocolchicoside

Causes & Risk Factors for Thiocolchicoside

Diagnostic studies for Thiocolchicoside

Treatment of Thiocolchicoside

Continuing Medical Education (CME)

CME Programs on Thiocolchicoside

International

Thiocolchicoside en Espanol

Thiocolchicoside en Francais

Business

Thiocolchicoside in the Marketplace

Patents on Thiocolchicoside

Experimental / Informatics

List of terms related to Thiocolchicoside

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Thiocolchicoside (Muscoril, Myoril, Neoflax) is a muscle relaxant with anti-inflammatory and analgesic effects.[3][4][5][6] It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent.[7][8] It has powerful convulsant activity and should not be used in seizure-prone individuals.[9][10][11]

Side effects

Side effect of thiocolchicoside can include nausea, somnolence, allergy and vasovagal reactions.[12]

Although Musle relaxant have major side effect of Sedation, but Thiocholchicoside is free from sedation effect possible due to non-interference with nicotinic receptors.[citation needed]

Pharmacokinetics

Thiocolchicoside is broken down in the body to a metabolite called 3-demethylthiocolchicine (also known as SL59.0955 or M2) that could damage dividing cells therefore inducing toxicity in the embryo, neoplastic changes and fertility reduction in males.[citation needed] Therefore recommended oral dose should not exceed 7 days and intramuscular dose duration should not exceed 5 days.Template:Medcn Local skin preparations are less toxic.

References

  1. 1.0 1.1 Perucca E, Poitou P, Pifferi G (1995). "Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers". European Journal of Drug Metabolism and Pharmacokinetics. 20 (4): 301–5. doi:10.1007/bf03190249. PMID 8983937.
  2. Sandouk P, Bouvier d'Yvoire M, Chretien P, Tillement JP, Scherrmann JM (January 1994). "Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers". Biopharmaceutics & Drug Disposition. 15 (1): 87–92. doi:10.1002/bdd.2510150108. PMID 8161719.
  3. Tüzün F, Unalan H, Oner N; et al. (September 2003). "Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain". Joint, Bone, Spine : Revue Du Rhumatisme. 70 (5): 356–61. doi:10.1016/S1297-319X(03)00075-7. PMID 14563464.
  4. Ketenci A, Basat H, Esmaeilzadeh S (July 2009). "The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study". Journal of the Turkish Society of Algology. 21 (3): 95–103. PMID 19780000.
  5. Soonawalla DF, Joshi N (May 2008). "Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm". Journal of the Indian Medical Association. 106 (5): 331–5. PMID 18839644.
  6. Ketenci A, Ozcan E, Karamursel S (July 2005). "Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain". International Journal of Clinical Practice. 59 (7): 764–70. doi:10.1111/j.1742-1241.2004.00454.x. PMID 15963201.
  7. Carta M, Murru L, Botta P; et al. (September 2006). "The muscle relaxant thiocolchicoside is an agonist of GABAA receptor function in the central nervous system". Neuropharmacology. 51 (4): 805–15. doi:10.1016/j.neuropharm.2006.05.023. PMID 16806306.
  8. Mascia MP, Bachis E, Obili N; et al. (March 2007). "Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes". European Journal of Pharmacology. 558 (1–3): 37–42. doi:10.1016/j.ejphar.2006.11.076. PMID 17234181.
  9. De Riu PL, Rosati G, Sotgiu S, Sechi G (August 2001). "Epileptic seizures after treatment with thiocolchicoside". Epilepsia. 42 (8): 1084–6. doi:10.1046/j.1528-1157.2001.0420081084.x. PMID 11554898.
  10. Giavina-Bianchi P, Giavina-Bianchi M, Tanno LK, Ensina LF, Motta AA, Kalil J (June 2009). "Epileptic seizure after treatment with thiocolchicoside". Therapeutics and Clinical Risk Management. 5 (3): 635–7. doi:10.2147/tcrm.s4823. PMC 2731019. PMID 19707540.
  11. Sechi G, De Riu P, Mameli O, Deiana GA, Cocco GA, Rosati G (October 2003). "Focal and secondarily generalised convulsive status epilepticus induced by thiocolchicoside in the rat". Seizure : the Journal of the British Epilepsy Association. 12 (7): 508–15. doi:10.1016/S1059-1311(03)00053-0. PMID 12967581.
  12. "Thiocolchicoside-induced liver injury". Mar 2011. Retrieved Dec 2014. Check date values in: |accessdate= (help)